AllianceBernstein’s Prelude Therapeutics PRLD Stock Holding History

AllianceBernstein’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-21,500	Closed	-$148K	–	3353
2022 Q1	$148K	Sell	21,500 -1,968	-8%	-$18K	﹤0.01%	3056
2021 Q4	$292K	Buy	23,468 +9,768	+71%	+$159K	﹤0.01%	2950
2021 Q3	$428K	Sell	13,700 -4,200	-23%	-$136K	﹤0.01%	2814
2021 Q2	$512K	Buy	17,900 +7,500	+72%	+$267K	﹤0.01%	2799
2021 Q1	$451K	Buy	10,400 +1,800	+21%	+$119K	﹤0.01%	2701
2020 Q4	$615K	Buy	+8,600	New	+$428K	﹤0.01%	2496

Other funds holding PRLD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AllianceBernstein's PRLD Position: Q2 2022 in Review

AllianceBernstein sold out of Prelude Therapeutics (PRLD) in Q2 2022, closing a stake of 21,500 shares — an estimated $148K sold.

AllianceBernstein first reported a position in PRLD in Q4 2020 and held it in 6 quarters. The position peaked at $615K in Q4 2020. 62 funds tracked by Wall St. Rank hold PRLD as of Q2 2022.

AllianceBernstein reported no remaining Prelude Therapeutics position as of Q2 2022 after selling out during the quarter.
AllianceBernstein sold 21,500 Prelude Therapeutics shares in Q2 2022, an estimated $148K.
AllianceBernstein first reported a position in Prelude Therapeutics in Q4 2020 and held it in 6 quarters.
AllianceBernstein's Prelude Therapeutics position peaked at $615K in Q4 2020.
62 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2022.

Based on AllianceBernstein's 13F filing for Q2 2022, filed 15 Aug 2022.